Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Alexander Bujotzek

Christian Klein

Pablo Umaña

Stefan Klostermann

Harald Duerr

Ekkehard Moessner

Pablo Umana

Peter Bruenker

Lydia Jasmin Hanisch

Johannes Sam

Joerg Zielonka

Christine Trumpfheller

Moritz Rapp

Joerg Benz

Wei Xu

Estelle Marrer-Berger

Marine Le Clech

Guy Georges

Georg Fertig

Sabine Imhof-Jung

Stefan Dengl

Joerg Moelleken

Petra Rueger

Georg Tiefenthaler

Jens Fischer

Maria Amann

Sabine Hoves

Sebastian Fenn

Tanja Fauti

Tina Weinzierl

Roland Staack

Meher Majety

Francesca Ros

Thomas Kraft

Claudia Kirstenpfad

Florian Lipsmeier

Laurene Pousse

Stéphane LeClair

Simon Patrick Keiser

Andreas Hinz

Eva Carina Sum

Stephane Leclair

Dietrich Tuerck

Janine Faigle

Carina Cantrill

Juergen Peter Bachl

Alejandro Carpy Gutierrez Cirlos

Alain Tissot

Anneliese Schneider

Maud Lea Mayoux

Helene Cecile Haegel

Stefan Lorenz

Clemens Wrzodek

Frederic Schultz

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-FAP clone 212

The present invention relates to anti-HLA-G antibodies and methods of using the same.

Anti-HLA-G antibodies and methods of use thereof

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/WT1

The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/MAGE-A4

The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules targeting OX40 and FAP

Growing community of inventors

Penzberg, Germany

Alexander Bujotzek